Rocket Lab’s $266 Million Defense Win Offers a Brief Respite from a Brutal Sell-Off
Published on 07/22/2026 at 14:12 | Redaktion boerse-global.de
Rocket Lab USA has secured a fixed-price contract worth $266 million from the US Space Force, covering twelve suborbital launches with an option for six additional missions. The award, issued by the Space Systems Command under contract number FA8818-26-C-B003, comes from a competitive bidding process that drew three proposals. Of the total sum, $112 million has already been obligated from fiscal year 2025 research and development funds.
The launches will take place at the Pacific Spaceport Complex in Alaska, with completion slated for December 31, 2028. Rocket Lab plans to use its HASTE vehicle, a suborbital variant derived from the Electron platform that the company has already deployed for hypersonic and test flights. The deal adds to a growing roster of government work: just weeks earlier, Rocket Lab launched a satellite for the Space Force under the “Tactically Responsive Space” program within 17 hours of receiving the order, setting a record for rapid-response capability. The company is also part of the National Security Space Launch program’s Phase 3, a framework that was recently expanded to $17 billion, where it sits alongside SpaceX, ULA, Blue Origin, and others in the Lane-1 mission pool.
The stock responded sharply to the news. In after-hours trading on July 21, shares surged as much as nine percent, building on a 4.46 percent gain during the regular session that closed at $68.67. The primary article reported a regular-session close of $69.12 with a 5.14 percent advance, reflecting slight differences in timing or data feeds. Either way, the reaction underscores how oversold the stock had become: the Relative Strength Index had dipped to 33.3, territory that often precedes a bounce on positive catalysts.
Yet the relief rally masks a deeper malaise. Rocket Lab’s shares have lost more than 31 percent over the past 30 days and remain roughly 54 percent below the 52-week high of $151.00 reached in late May. The broader space sector has been cooling since early June, when Blue Origin’s New Glenn rocket exploded during a test and speculation about a lower valuation for SpaceX’s anticipated IPO rippled through the market. Rocket Lab lost more than 15 percent in a single trading session during that rout. The stock’s price-to-sales ratio, which had soared to 91 during last year’s rally from below 20 twelve months earlier, has since compressed to around 56.7.
Should investors sell immediately? Or is it worth buying Rocket Lab USA?
Operationally, the company continues to post impressive growth. First-quarter 2026 revenue hit $200.35 million, a 63.4 percent increase year-over-year, while the loss per share of $0.07 matched analyst expectations. The backlog stands at a record $2.2 billion, with more launch contracts signed in that single quarter than in all of 2025. For the full year, management guided for revenue between $850 million and $900 million and EBITDA of $90 million to $110 million. The planned acquisition of satellite operator Iridium, which would create an end-to-end space services offering, adds another layer of growth potential.
But the market is fixated on two concerns that have overwhelmed the operational story. The first is the Neutron rocket program. The larger, reusable launch vehicle, designed to carry 28,000 pounds to orbit, was originally scheduled for a February 2026 debut but has been pushed to late 2026. CEO Peter Beck has emphasized the importance of ongoing test stands for Neutron’s development without committing to a new firm date. Competitors including Firefly Aerospace, Relativity Space, Stoke Space, Isar Aerospace, and Blue Origin are all advancing their own medium-lift vehicles, raising the stakes for Rocket Lab to deliver.
The second concern is dilution. Rocket Lab’s acquisition strategy and persistent cash burn have fueled speculation about additional capital raises. Insider selling has been relentless: Beck sold 990,960 shares at $82.86 on July 8, and insiders collectively unloaded $362.8 million worth of stock over the past three months with zero insider purchases. The secondary article notes a beta of 2.54, confirming the stock’s extreme volatility relative to the broader market.
Rocket Lab USA at a turning point? This analysis reveals what investors need to know now.
Analyst sentiment remains cautiously optimistic despite the headwinds. Of 22 analysts covering the stock, three rate it a “Strong Buy,” twelve a “Buy,” six a “Hold,” and one a “Sell.” The average price target of $110.18 implies upside of roughly 59 percent from recent levels. Simply Wall St’s fair-value estimate sits at $105.00. A separate valuation model gives the company a score of 71 out of 100, citing solid financial strength but weak profitability.
Whether the new defense contract can restore lasting investor confidence will likely depend on how credible the Neutron timeline proves over the coming months. For now, Rocket Lab remains a story of operational momentum colliding with market skepticism — and a $266 million award, while welcome, is only one piece of a much larger puzzle.
Ad
Rocket Lab USA Stock: New Analysis - 22 July
Fresh Rocket Lab USA information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
